Effects of NOP-Related Ligands in Nonhuman Primates.

Related Articles:

• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. April 12, 2019 Related ArticlesReceptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. Biomolecules. 2019 Apr 09;9(4): Authors: Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W Abstract Levodopa (LD) is the most effective drug in the treatment of Parkinson's disease (PD). However, although it represents the "gold standard" of PD therapy, LD can cause side effects,…
• Designing Functionally Selective Non-Catechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity. August 8, 2019 Related ArticlesDesigning Functionally Selective Non-Catechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity. ACS Chem Neurosci. 2019 Aug 06;: Authors: Martini ML, Ray C, Yu X, Liu J, Pogorelov V, Wetsel WC, Huang XP, McCorvy J, Caron MG, Jin J Abstract Dopamine receptors are important G protein-coupled receptors (GPCRs) with therapeutic opportunities for treating Parkinson's Disease (PD) motor…
• Cancer and the dopamine D2 receptor: a pharmacological perspective. April 20, 2019 Related ArticlesCancer and the dopamine D2 receptor: a pharmacological perspective. J Pharmacol Exp Ther. 2019 Apr 18;: Authors: Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ Abstract The dopamine D2 receptor (D2R) family is upregulated in many cancers, and tied to stemness, while cancer risk may correlate with dopamine-related disorders such as schizophrenia and Parkinson's disease. D2R antagonists also have…
• Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders. July 6, 2019 Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders. Pharmacol Res. 2019 Jul 02;:104338 Authors: Domenici MR, Ferrante A, Martire A, Chiodi V, Pepponi R, Tebano MT, Popoli P Abstract Adenosine A2A receptor (A2AR) is a G-protein coupled receptor that regulates several important functions in the central nervous system. Large amount of preclinical data suggests that the A2AR could…
• Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. July 24, 2019 Related ArticlesAdenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. Curr Pharm Des. 2019 Jul 16;: Authors: Al-Attraqchi OHA, Attimarad M, Venugopala KN, Nair A, Al-Attraqchi NHA Abstract Adenosine receptors (ARs) are a class of G-protein coupled receptors (GPCRs) that are activated by the endogenous substance adenosine. ARs are classified into 4 subtype receptors, namely,…
• Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. July 20, 2019 Related ArticlesEffects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis. 2019;10:2040622319862691 Authors: Onoviran OF, Li D, Toombs Smith S, Raji MA Abstract Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug-drug and drug-disease interactions in these…
• P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future. July 24, 2019 Related ArticlesP1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future. Curr Pharm Des. 2019 Jul 16;: Authors: Borah P, Deka S, Mailavaram RP, Deb PK Abstract BACKGROUND: Adenosine mediates various physiological and pathological conditions by acting on its four P1 receptors (A1, A2A, A2B and A3 receptors). Omnipresence of P1 receptors and their activation, exert a…
• Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. October 4, 2019 Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. Expert Opin Ther Targets. 2019 Oct 03;: Authors: Leitner GR, Wenzel TJ, Marshall N, Gates EJ, Klegeris A Abstract Introduction: Adverse immune activation contributes to many central nervous system (CNS) disorders. All main CNS cell types express toll-like receptor 4 (TLR 4). This receptor is critical for a…
• GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. November 11, 2019 Related ArticlesGIP has neuroprotective effects in Alzheimer and Parkinson's disease models. Peptides. 2019 Nov 06;:170184 Authors: Zhang ZQ, Hölscher C Abstract Glucose-dependent Insulinotropic polypeptide (GIP) is a peptide hormone of the incretin family. It has growth factor properties and can re-activate energy utilization. In progressive neurodegenerative disorders such as Alzheimer's and Parkinson's disease, energy utilization is much reduced, and GIP…
• Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders. August 6, 2019 Related ArticlesPositive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders. Adv Pharmacol. 2019;86:273-305 Authors: Svensson KA, Hao J, Bruns RF Abstract The dopamine D1 receptor plays an important role in motor activity, reward, and cognition. Efforts to develop D1 agonists have been mixed due to poor drug-like properties, tachyphylaxis, and inverted U-shaped…
• Antinociceptive effects of treadmill exercise in a rat model of Parkinson's disease: the role of cannabinoid and opioid receptors. November 8, 2019 Antinociceptive effects of treadmill exercise in a rat model of Parkinson's disease: the role of cannabinoid and opioid receptors. Brain Res. 2019 Nov 04;:146521 Authors: Binda KH, Real CC, Ferreira AFF, Britto LRG, Chacur M Abstract In addition to motor symptoms, Parkinson's disease (PD) presents high prevalence of painful symptoms responsible for worsening quality of life of PD patients. Physical…
• 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. June 28, 2019 Related Articles5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. Pharmacol Rev. 2019 Jul;71(3):383-412 Authors: Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, Zirak MR, Beaulieu JM Abstract 5-HT3 receptor antagonists, first introduced to the market in the mid-1980s, are proven efficient agents to counteract chemotherapy-induced emesis. Nonetheless, recent investigations have shed light on unappreciated dimensions…
• Enhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. May 17, 2019 Related ArticlesEnhanced mu opioid receptor-dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. Mov Disord. 2018 02;33(2):310-320 Authors: Ponterio G, Tassone A, Sciamanna G, Vanni V, Meringolo M, Santoro M, Mercuri NB, Bonsi P, Pisani A Abstract BACKGROUND: Mu opioid receptor activation modulates acetylcholine release in the dorsal striatum, an area deeply involved in motor function, habit formation, and…
• Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold. March 19, 2019 Related ArticlesSynthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold. Medchemcomm. 2019 Feb 01;10(2):315-325 Authors: Baumeister S, Schepmann D, Wünsch B Abstract The involvement of NMDA receptors containing the GluN2B subunit in neurodegenerative disorders including Alzheimer's and Parkinson's disease renders this NMDA receptor subtype an interesting pharmacological target. The aim of this study was the…
• Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A2A AR ligands with in vivo efficacy against animal model of Parkinson's disease. April 2, 2019 Related ArticlesSynthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A2A AR ligands with in vivo efficacy against animal model of Parkinson's disease. Bioorg Chem. 2019 Mar 19;87:601-612 Authors: Rohilla S, Bansal R, Kachler S, Klotz KN Abstract In the present study, an attempt has been made to develop a new series of 1,3,7,8-tetrasubstituted xanthine…
• Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease. July 21, 2017 Related ArticlesOpioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017 Jul 19;: Authors: Cilia R, Asselta R, Cereda E, Benfante R, Barbella G, Vallauri D, Marabini L, Fornasari D, Goldwurm S, Pezzoli G PMID: 28724719 [PubMed - as supplied by publisher]
• GLP-1 Agonists – the facts August 7, 2018 What are GLP-1 Agonists and why are these drugs important to CPT’s research? Liraglutide, Lixisenatide and Exenatide (the synthetic form of Exendin-4) belong to a group of safe and well tolerated drugs called Glucagon-like peptide (GLP-1) agonists designed to mimic the action of human gut hormones or incretins (see Christian Holscher's pre-clinical work). The glucagon-like peptide-1 (GLP-1) receptor agonists increase…
• GLP-1 Agonists – the facts September 18, 2019 What are GLP-1 Agonists and why are these drugs important to CPT’s research? Liraglutide, Lixisenatide and Exenatide (the synthetic form of Exendin-4) belong to a group of safe and well tolerated drugs called Glucagon-like peptide (GLP-1) agonists designed to mimic the action of human gut hormones or incretins (see Christian Holscher's pre-clinical work). The glucagon-like peptide-1 (GLP-1) receptor agonists increase…
• Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. November 11, 2019 Related ArticlesCannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. Neuropharmacology. 2019 Nov 07;:107808 Authors: Crivelaro do Nascimento G, Ferrari DP, Guimaraes FS, Del Bel EA, Bortolanza M, Ferreira-Junior NC Abstract Medications that improve pain threshold can be useful in the pharmacotherapy of Parkinson's disease (PD). Pain is a prevalent PD's non-motor symptom with a higher prevalence…
• Structure-dependent Activation of Gene Expression by Bis-indole and Quinoline-derived Activators of Nuclear Receptor 4A2. May 19, 2019 Structure-dependent Activation of Gene Expression by Bis-indole and Quinoline-derived Activators of Nuclear Receptor 4A2. Chem Biol Drug Des. 2019 May 18;: Authors: Li X, Tjalkens RB, Shrestha R, Safe S Abstract Bis-indole derivatives including 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane (DIM-C-pPhCl) and substituted quinolines such as chloroquine (CQ) and amodiaquine (AQ) are nuclear receptor 4A2 (NR4A2, Nurr1) ligands and they exhibit anti-inflammatory activities in mouse…